{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:29:31Z","timestamp":1725251371022},"reference-count":42,"publisher":"SLACK, Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate initial treatment of high-risk retinopathy of prematurity (ROP) with low-dose intravitreal ranibizumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>Case series of premature infants with high-risk pre-threshold or threshold posterior ROP receiving primary therapy with 0.2 mg ranibizumab. Pre-treatment and post-injection examination, RetCam (Clarity Medical Systems, Pleasanton, CA) images, fluorescein angiography, resolution of ROP and plus disease, and stability of examinations were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Eight eyes of four infants received primary ranibizumab treatment. Plus disease resolved within 48 hours of unilateral injection, and there was no change in ROP appearance in the contralateral eye. Complete resolution of stage 3 ROP occurred 1 week after injection. Recurrent progressive stage 2 or 3 ROP in mid to anterior zone 2 was noted 8 to 11 weeks after ranibizumab in all eyes. Treatment of recurrent ROP with peripheral laser led to complete ROP regression. Comparison of images before ranibizumab injection to images after ROP recurred demonstrated anterior retinal growth. Retina examinations remained stable without ROP recurrence or detachment at follow-up 8 to 18 months after ranibizumab injection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Intravitreal ranibizumab induces rapid, complete regression of high-risk posterior ROP with continued retina growth peripherally. The potential for recurrent ROP after a single 0.2 mg ranibizumab injection for posterior ROP requires vigilant monitoring. Subsequent peripheral laser for ROP recurrences may spare the posterior retina from photocoagulation effects.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                . 2015;46:432\u2013438.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20150422-05","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T18:52:24Z","timestamp":1449773544000},"page":"432-438","source":"Crossref","is-referenced-by-count":19,"title":["Primary Intravitreal Ranibizumab for High-Risk Retinopathy of Prematurity"],"prefix":"10.3928","volume":"46","author":[{"given":"Caroline R.","family":"Baumal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger A.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordana G.","family":"Fein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.098582"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.229"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12053"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)01017-X"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.040"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-007-9066-0"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.08.050"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.592"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31820d4000"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000338623"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302276"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2010.05.011"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2012-302365"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.400"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02351.x"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-620X.106103"},{"key":"e_1_3_1_18_2","first-page":"225","article-title":"Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience","volume":"79","author":"Orozco-Gomez LP","year":"2011","unstructured":"Orozco-Gomez LP, Hernandez-Salazar L, Moguel-Ancheita S, et al. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. Cir Cir. 2011;79:225\u2013232.","journal-title":"Cir Cir"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2011.11.002"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.07.012"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181cb6151"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-2996"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182993d5f"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.3928\/01913913-20130625-01"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Gilbert C Fielder A Gordillo L et al. Characteristics of infants with severe retinopathy of prematurity in countries with low moderate and high levels of development: implications for screening programs. 2005; 115 :e518\u2013e525.","DOI":"10.1542\/peds.2004-1180"},{"key":"e_1_3_1_27_2","first-page":"233","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity randomized trial","volume":"102","author":"Good WV","year":"2004","unstructured":"Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity randomized trial. Trans Am Ophthalmol Soc. 2004;102:233\u2013248.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000244285.79004.e6"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.10.027"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2010.08.006"},{"key":"e_1_3_1_31_2","article-title":"Plasma level of VEGF in ROP after intravitreal injection of bevacizumab","volume":"52","author":"Lee SJ","year":"2011","unstructured":"Lee SJ, Kim SY, Yoo BC, Kim HW, Kim YH. Plasma level of VEGF in ROP after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2011;52: ARVO abstract 3165.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02469.x"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302451"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02240.x"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.400"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2009.03.006"},{"key":"e_1_3_1_38_2","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","author":"Harder BC","year":"2013","unstructured":"Harder BC, Baltz SV, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol. 2013. Epub ahead of print","journal-title":"Acta Ophthalmol"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2012.02552.x"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.04.026"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e3283423f35"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/23258160-20150422-05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T23:56:49Z","timestamp":1683071809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20150422-05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.3928\/23258160-20150422-05"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20150422-05","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}